ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

Adriana Miguel-Álvarez1, luis M Amezcua Guerra2, María L Loredo-Mendoza1, Luis H. Silveira Torre3 and Angélica Vargas Guerrero4, 1Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, 2Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 3Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 4Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), dermatomyositis, Myopathies, Myositis

Session Information

Date: Sunday, November 17, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to multiple versus single positivity myositis specific antibodies (MSA) determined by line immunoassay (LIA). In patients with muscle biopsy, differences between groups were also analyzed.

Methods: We retrospectively reviewed all the patients who satisfy 2017 EULAR/ACR classification criteria for adult and juvenile IIM and who had MSA panel by LIA between March 2023 and May 2024. Due to the number of patients, only anti-Mi2 and anti-TIF1γ were subanalyzed. Chi-square, Fisher’s, Mann-Whitney U and Kruskall Wallis tests were used for association between groups. Two-tail p value < 0.05 was considered statistically significant.

Results: Fifty-seven patients were included; forty-two (73%) female. IIM diagnosis distribution is in table 1. Fifty-four patients (94.7%) had ≥1 MSA; thirty-seven (64.9%) were single MSA positive and 17 (29.8%) multiple. Anti-Mi2 was the most common MSA, it was present in 25 patients (44%), followed by anti-TIF1γ in 17 (30%), anti-MDA5 in 12 (21%), anti-SRP in 9 (16%), anti-SAE in 8 (12%), anti-Jo-1 and anti-PL-7 7 each one (12%), anti-PL-12 in 5 (9%), anti-OJ in 4 (7%), anti-NXP2 and anti-EJ 2 each one (3%). In general, no differences in activity were observed between groups (table 1). Initial LDH levels were higher in patients with single MSA positivity; in those with multiple positivity, the use of prednisone and comorbidities were more frequent. Anti-PM/Scl 75 and anti-Ku were present only in multiple positivity group (table 1). Twenty-eight patients (49.1%) had muscle biopsy available. Perifascicular atrophy was identified in single MSA positivity group, while chronic endomysial infiltrate in multiple positivity (figure 1). Heliotrope rash and nail dystrophy were more frequent in negative anti-Mi2; while positive anti-Mi2 was related with dysphagia. Lower MMT-8 scores and higher creatin kinase levels were observed in high positive anti-Mi2 (table 2). Patients with strongly positive anti-TIF1γ had lower LDH and C reactive protein. Dermatological features were more frequent in stronger positive anti- TIFγ antibodies (table 2); the 6 patients with low positive anti-TIF1y antibodies had hypothyroidism and 2 had breast cancer

Conclusion: Strong positivity by LIA seems to have greater clinical and serological correlations, as anti-Mi2 and anti-TIF1γ in this study. Few differences were found between multiple positivity versus single positivity MSA: glucocorticoid use and comorbidities were more frequent in the former. Presence of anti-PM/Scl 75, anti-Ku and endomysial chronic infiltration was present only in multiple MSA. Studies with more patients are required to evaluate if there are clinical and histological differences in patients with one or multiple MSA, including comparisons with specific tests as ELISA.

Supporting image 1

Supporting image 2

Figure 1. Four cases of inflammatory myopathy photomicrographs. A and B show two cases with endomysial lymphocytic inflammatory infiltrate (arrows) and degenerative myocyte changes accompanied by phagocytic macrophages (arrow heads) C and D depict perimysial mononuclear inflammatory infiltrate (arrows) and perifascicular atrophy (arrow heads). Original magnification 400X, scale bar 25µm.

Supporting image 3


Disclosures: A. Miguel-Álvarez: None; l. Amezcua Guerra: None; M. Loredo-Mendoza: None; L. Silveira Torre: None; A. Vargas Guerrero: None.

To cite this abstract in AMA style:

Miguel-Álvarez A, Amezcua Guerra l, Loredo-Mendoza M, Silveira Torre L, Vargas Guerrero A. Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characterization-of-the-clinical-presentation-of-idiopathic-inflammatory-myopathies-according-to-the-profile-of-specific-autoantibodies-with-multiple-positivity/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-the-clinical-presentation-of-idiopathic-inflammatory-myopathies-according-to-the-profile-of-specific-autoantibodies-with-multiple-positivity/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology